ライフサイエンスコーパス: anogenital

1 was anogenital location, but few cases were anogenital.

2 ysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.

3 man papillomavirus infection and its related anogenital abnormalities/cancer.

4 highlight differences between the effects of anogenital and cutaneous HPV on epithelial AKT activity

5 Other HPV-associated anogenital and head and neck cancers are predicted to af

6 papillomaviruses (HPVs) (e.g., HPV-16) cause anogenital and head and neck cancers, and low-risk HPVs

7 k human papillomaviruses (HPV) cause certain anogenital and head and neck cancers.

8 ions with high-risk HPVs are associated with anogenital and head and neck cancers.

9 regulate epidermal differentiation and cause anogenital and head and neck squamous cell carcinomas (S

10 evalent oncogenic genotype in HPV-associated anogenital and oral cancers.

11 HPV-16, are etiologic agents of a variety of anogenital and oral malignancies, including nearly all c

12 HSV-1-seropositive healthy adults collected anogenital and oral swabs, respectively, 4 times per day

13 in types of HPV can cause cervical and other anogenital and oropharyngeal cancer, and other types of

14 al types of human papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous

15 l cervical cancers and a proportion of other anogenital and oropharyngeal cancers.

16 papillomaviruses (HPVs) are a major cause of anogenital and oropharyngeal cancers.

17 fection that is a major cause of noncervical anogenital and oropharyngeal cancers.

18 Clearance of anogenital and oropharyngeal HPV infections is attribute

19 elated carcinomas and premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnos

20 nd are linked to several other tumors of the anogenital and oropharyngeal regions.

21 ithelial cancers, including those within the anogenital and oropharyngeal tracts.

22 res include toe syndactyly, telecanthus, and anogenital and renal malformations.

23 oncogenic HPV type associated with cervical, anogenital, and oropharyngeal cancers.

24 ll cancer cases worldwide, notably cervical, anogenital, and oropharyngeal cancers.

25 ) but lichen sclerosus is most common in the anogenital area, where it causes intractable itching and

26 later malignancies of the head and neck and anogenital area.

27 mples were collected separately from several anogenital areas for detection of HPV6/11/16/18/31/33/35

28 icipants collected daily swabs from oral and anogenital areas for HSV detection with a quantitative p

29 ransplantation were significantly increased: anogenital cancer (HR, 3.13; confidence interval [CI], 1

30 ividuals with a history of an HPV-associated anogenital cancer and HIV-infected men are at increased

31 pport an important role for HPV infection in anogenital cancer at all sites.

32 y was designed to compare HPV exposure among anogenital cancer cases and matched controls.

33 Cases (1782) of anogenital cancer diagnosed in the Seattle area from 197

34 were HIV negative and reported no history of anogenital cancer were recruited into the HPV Infection

35 p53 gene mutation is an infrequent event in anogenital cancer, apparently due to the action of HPV E

36 In addition to their role in anogenital cancer, human papillomaviruses (HPVs) are als

37 While many HR HPV types are common in anogenital cancer, over 90% of HPV-positive HNCs harbor

38 risk HPV types due to their association with anogenital cancer.

39 most infections are benign, some progress to anogenital cancer.

40 ial to target a wide range of HPVs linked to anogenital cancer.

41 Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12

42 viruses (HPVs) that cause cervical and other anogenital cancers also are found in approximately 25% o

43 Human papillomaviruses (HPV) cause anogenital cancers and anogenital HPV infection up-regul

44 PV) are the causative agents of cervical and anogenital cancers and are associated with 5% of all hum

45 s with GW have a long-term increased risk of anogenital cancers and head and neck cancers.

46 HPV-16), are etiologic agents of a subset of anogenital cancers and head and neck squamous cell carci

47 6, is central to the development of squamous anogenital cancers and their precursor lesions, termed "

48 roups primarily associated with cervical and anogenital cancers appear to follow two distinct evoluti

49 Anogenital cancers are associated with approximately 13

50 Cervical and anogenital cancers are induced by the high-risk types of

51 uman papillomaviruses (HPVs) associated with anogenital cancers are largely responsible for the oncog

52 Human papillomavirus-related anogenital cancers are theoretically preventable.

53 31, and 51 are the etiologic agents of many anogenital cancers including those of the cervix.

54 Conversely, the incidence of anogenital cancers may decline in the future among HIV-p

55 6 antibodies are present before diagnosis of anogenital cancers within the same cohort.

56 such as HPV16, cause cervical cancers, other anogenital cancers, and a subset of head and neck cancer

57 the vast majority of cervical cancers, other anogenital cancers, and a subset of head and neck squamo

58 the vast majority of cervical cancer, other anogenital cancers, and a subset of head and neck squamo

59 cancer and a significant proportion of other anogenital cancers, as well as both oral and pharyngeal

60 ), the causative agents of most cervical and anogenital cancers, encode three oncogenes.

61 h-risk human papillomaviruses (HR-HPV) cause anogenital cancers, including cervical cancer, and head

62 mavirus (HPV) is the main etiologic agent of anogenital cancers, including cervical cancer, but littl

63 viruses are causative agents of cervical and anogenital cancers.

64 strongly associated with cervical and other anogenital cancers.

65 e the causative agents of cervical and other anogenital cancers.

66 responsible for the majority of cervical and anogenital cancers.

67 a and other HPV-associated oropharyngeal and anogenital cancers.

68 agent of warts and are associated with many anogenital cancers.

69 s, which are present in a high percentage of anogenital cancers.

70 illomaviruses (HPVs) are etiologic agents of anogenital cancers.

71 ses (HPVs) are implicated in the etiology of anogenital cancers.

72 the etiological agents of cervical and other anogenital cancers.

73 f anal cancer but rare for other HPV-related anogenital cancers.

74 aviruses (HPV) that cause cervical and other anogenital cancers.

75 HPV) infections are necessary causes of most anogenital cancers.

76 The role of human papillomavirus (HPV) in anogenital carcinogenesis is firmly established, but evi

77 The majority of human anogenital carcinomas show evidence of papillomavirus in

78 n, and may lead to clinical sequelae such as anogenital condylomata and cervical squamous cell carcin

79 t human papillomavirus types correlated with anogenital cytologic abnormalities, an important area in

80 apillomavirus types and a high prevalence of anogenital cytologic abnormalities.

81 mporal fate maps, we present a new model for anogenital development and suggest that disruptions at s

82 ow the fate of posterior gut endoderm during anogenital development.

83 reduction in human papillomavirus-associated anogenital disease with both quadrivalent and bivalent v

84 fected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosu

85 Body mass, body fat, sex, anogenital distance (AGD) (a proxy for androgenization)

86 Normal reproductive tract development and anogenital distance (AGD) are programmed within the MPW,

87 asis of masculinization, as indicated by the anogenital distance (AGD) at birth and weaning, in the r

88 Anogenital distance (AGD) in animals is a sensitive biom

89 Anogenital distance (AGD) is a sensitive biomarker of th

90 Anogenital distance (AGD), the distance from the anus to

91 h in male rats, all of which correlated with anogenital distance (AGD).

92 Two small studies report shorter anogenital distance among male infants with higher gesta

93 liver chemical profiles, masculinising fetal anogenital distance and greatly increasing the number of

94 Measurements of anogenital distance and penile dimensions were taken, an

95 f a stress-sensitive phenotype and shortened anogenital distance in adult F2-S males.

96 eriments, in utero exposure to DDE decreases anogenital distance in male offspring.

97 d spermatogenesis, preputial separation, and anogenital distance in males and day of vaginal opening

98 esis that in utero exposure to DDE decreases anogenital distance in newborn human males.

99 effects of weaned litter sex composition and anogenital distance on several life-history and fitness

100 d to reduced androgen action as reflected by anogenital distance or penile dimensions at birth.

101 stosterone action such as testis descent and anogenital distance remained normal.

102 In these models, anogenital distance serves as a measure of fetal androge

103 r of male and female offspring, body weight, anogenital distance, vaginal opening, testes descent, es

104 t the number of males in a litter influenced anogenital distance.

105 that masculinized females, those with larger anogenital distances, were less likely to survive their

106 omes, such as development of bronchiectasis, anogenital dysplasia, or invasive cancer.

107 esions caused by low-risk HPV-types, whereas anogenital dysplasias are potential cancer precursors as

108 Subjects underwent anogenital examinations and sampling of the penis, scrot

109 ated, we recommend that TOC be performed for anogenital gonorrhoea at least 7 or 14 days after admini

110 We included patients with anogenital gonorrhoea visiting the Sexually Transmitted

111 tients presenting with chronic pseudotumoral anogenital herpes simplex type 2 (HSV-2) infections were

112 promising vaccine candidates for controlling anogenital HPV disease and are now being evaluated as a

113 ort the concept of oral immunization against anogenital HPV disease and suggest that clinical studies

114 o compare the potential of the full range of anogenital HPV genotypes to induce cytopathic effects, w

115 s study examined the determinants of initial anogenital HPV infection among teenage MSM.

116 ent strategies are not effective in clearing anogenital HPV infection and need improvement.

117 development of external genital lesions and anogenital HPV infection in boys and men.

118 maviruses (HPV) cause anogenital cancers and anogenital HPV infection up-regulates AKT activity.

119 he most important modifiable risk factor for anogenital HPV infection.

120 ule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased inci

121 We find that, in contrast to anogenital HPVs, cutaneous HPV8 early genes down-regulat

122 Infection with high-risk anogenital HPVs, such as HPV type 16 (HPV16), is associa

123 Anogenital HSV-2 cultures were positive on 405 (9.7%) of

124 y of resiquimod 0.01% gel for reducing human anogenital HSV-2 mucosal reactivation.

125 ation (CRT) and is typically associated with anogenital human papilloma virus infection.

126 nitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in H

127 Anogenital human papillomavirus (HPV) is common among me

128 Anogenital human papillomavirus infection remains highly

129 omavirus burden in HIV-infected individuals; anogenital human papillomavirus types and type-specific

130 The incidence of anogenital human papillomavirus-related cancers remains

131 In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate

132 As the modes of transmission of anogenital infections with HPV and HSV are unclear, an e

133 Sublineages B1 and B3 were associated with anogenital infections, indicating a potential lesion-spe

134 n areas of somatosensory nuclei that receive anogenital input together with the temporal corresponden

135 the maximum dose in 29 women with high-grade anogenital intraepithelial neoplasia (AGIN).

136 who treat anogenital warts, oral warts, and anogenital intraepithelial neoplasias (eg, cervical intr

137 including proximity, approach, huddling, and anogenital investigation in response to novel conspecifi

138 portance: Human papillomavirus (HPV)-induced anogenital lesions are very frequent in men who have sex

139 y improve our ability to accurately diagnose anogenital lesions due to herpes infection.

140 Four of seven patients with two distinct anogenital lesions had different HPV types in the lesion

141 08 participants (174 men and 334 women) with anogenital lesions were included; 260 HSV-2 and 73 HSV-1

142 Paired samples from anogenital lesions were tested using the BD ProbeTec HSV

143 tients developed chronic, hypertrophic HSV-2 anogenital lesions with multilesional presentation in 7

144 The treatment of choice for anogenital lichen sclerosus is potent topical corticoste

145 on, perineural invasion, and ear, temple, or anogenital location were risk factors associated with po

146 azard ratio, 3.6 [95% CI, 1.1-12.0]), as was anogenital location, but few cases were anogenital.

147 a new tool for investigating the etiology of anogenital malformations in humans.

148 Sixteen anogenital malignancies (1.6%) were found: vulva (n=6),

149 A high number of anogenital malignancies developed in our cohort, which a

150 omaviruses (HPV) which are commonly found in anogenital malignancies express a viral E7 oncoprotein w

151 and likely contribute to the development of anogenital malignancies in vivo.

152 le renal transplant recipients who developed anogenital malignancies were retrospectively analyzed.

153 o develop human papillomavirus (HPV)-related anogenital malignancies.

154 tion to prevent morbidity and mortality from anogenital malignancies.

155 iate surrogate biomarkers for HPV-associated anogenital neoplasia trials.

156 factor in determining the natural history of anogenital neoplasia.

157 We review the recent literature on anogenital neoplasms in AIDS, with emphasis on cancers a

158 Most anogenital neoplasms occurring with increased frequency

159 he efficacy of HAART therapy for HPV-induced anogenital neoplasms, despite efficacy in improving dise

160 ch as mounting, pelvic thrust, solicitation, anogenital olfactory investigation, and emission of comp

161 ever the lineage of cells that gives rise to anogenital organs remains poorly understood.

162 f anorectal and genitourinary (collectively, anogenital) organs occur at a high frequency in humans,

163 Disruption of Shh function during the anogenital phase causes coordinated anorectal and genito

164 on is divisible into two temporal phases; an anogenital phase, during which Shh regulates outgrowth a

165 A clinical overview of female anogenital posttransplantation malignancies and possible

166 HPV)-related cutaneous and genital warts and anogenital (pre)cancer.

167 e 16 have been implicated in the etiology of anogenital premalignant and malignant lesions.

168 human papillomaviruses (HPVs) are linked to anogenital preneoplastic lesions and cancer.

169 and 10(3.3) copies/mL, respectively, during anogenital reactivation and 10(3.7) and 10(3.0) copies/m

170 Lesions were reported in only 3 (7%) of 44 anogenital reactivations and 1 (8%) of 13 oral reactivat

171 Twenty-four percent of anogenital reactivations and 21% of oral reactivations l

172 l reactivations lasted < or =6 h, and 49% of anogenital reactivations and 39% of oral reactivations l

173 ted high-grade lesions and carcinomas in the anogenital region and oropharynx between 1990 and 2015 w

174 The entire anogenital region and semen were sampled.

175 cell carcinomas (SCCs) of the head and neck, anogenital region and skin.

176 at the mucosal sites including those of the anogenital region and the oral cavity.

177 risk of carcinomas of the head and neck and anogenital region, and a small continuing risk of leukem

178 t receive somatosensory information from the anogenital region.

179 ndrome, which is characterized by hand/foot, anogenital, renal, and ear anomalies, including sensorin

180 noncutaneous squamous cell carcinoma (SCC), anogenital SCC, inability to extract cSCC data from othe

181 Our results underline the importance of anogenital screening and monitoring before and periodica

182 ty-three men in 2 US cities were tested at 6 anogenital sites and in semen for 37 types of HPV.

183 association of HPV DNA with cancer at other anogenital sites has produced less consistent results.

184 ed States for 37 HPV types in samples from 5 anogenital sites.

185 in itching, pain, edema, and staining of the anogenital skin associated with the active treatment.

186 lammatory disease that most commonly affects anogenital skin of postmenopausal women.

187 hyperkeratosis confined to palms, soles, and anogenital skin, whereas the other two had more severe,

188 s a known risk factor for the development of anogenital squamous cell carcinomas (SCCs).

189 e first target cells to encounter HIV in the anogenital stratified squamous mucosa during sexual tran

190 HSV-2-seropositive Ugandan adults collected anogenital swab specimens for HSV DNA quantification by

191 Specimens included daily anogenital swabs (for HSV DNA polymerase chain reaction

192 weekly for 3 weeks and then collected daily anogenital swabs for 60 days for HSV DNA polymerase chai

193 ymptomatic genital HSV-2 infection collected anogenital swabs for HSV-2 DNA polymerase chain reaction

194 prepare infectious stocks of two additional anogenital tissue-targeting human papillomaviruses (HPVs

195 cinoma and a significant percentage of other anogenital tract and oral carcinoma.

196 They are the causative agents of anogenital tract and some oropharyngeal cancers.

197 et of human papillomaviruses that infect the anogenital tract and the upper aero-digestive tract is t

198 h as HPV-16 and HPV-18 cause the majority of anogenital tract carcinomas, including cervical cancer,

199 ontribute to a number of other tumors of the anogenital tract, as well as oral cancers.

200 PV) types, including the oral cavity and the anogenital tract.

201 HPV infections were analyzed in all primary anogenital tumors and possible (multifocal) premalignanc

202 fections and human papillomavirus-associated anogenital tumors are more prevalent in HIV-infected tha

203 espite highly active antiretroviral therapy, anogenital tumors may continue to increase in this popul

204 nfection (RR 0.50, 95% CI 0.34-0.74]) and in anogenital warts (0.86 [95% CI 0.79-0.94]) occurred in g

205 Anogenital warts (AGWs) are considered benign lesions ca

206 guidelines on human papillomavirus (HPV) and anogenital warts (AGWs), a review of the literature was

207 en therapy has been used in the treatment of anogenital warts (AGWs), but it has not been compared wi

208 History of smoking and anogenital warts and blood specimens for measurement of

209 with men (MSM) have a high lifetime risk of anogenital warts and cancers related to infection with h

210 omaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas.

211 e 6 (HPV6) is the major etiological agent of anogenital warts and laryngeal papillomas and has been i

212 avirus 11 (HPV11) is an etiological agent of anogenital warts and laryngeal papillomas and is include

213 Substantial declines in anogenital warts and male HPV-related cancer incidence a

214 Anogenital warts are a common disorder associated with s

215 riods by 68% (RR 0.32, 95% CI 0.19-0.52) and anogenital warts decreased significantly by 61% (0.39, 0

216 Anogenital warts in patients who are HIV+ should be eval

217 Thus, topical imiquimod treatment of anogenital warts led to significant increases in local p

218 uded testing for HPV infection in women with anogenital warts or other sexually transmitted diseases,

219 Additionally, significant reductions in anogenital warts were also reported in boys younger than

220 ctiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous le

221 ast one HPV-related endpoint: HPV infection, anogenital warts, and high-grade cervical lesions.

222 transmission to healthcare workers who treat anogenital warts, oral warts, and anogenital intraepithe

223 , and other types of HPV are associated with anogenital warts.

224 PV 6 and 11, which cause 90% of the cases of anogenital warts.

225 WIL) from patients with clinically diagnosed anogenital warts.

226 than 18 years with between 2 and 50 external anogenital warts.

227 e effective than placebo in the treatment of anogenital warts.